Stonehaven

Stonehaven, founded in 2001 and headquartered in New York City, is a global FinTech platform focused on private capital markets. It serves a diverse community of investment bankers and placement agents, facilitating transactions across various asset classes, including real estate, private equity, venture capital, private credit, hedge funds, and mergers and acquisitions. The firm engages with clients across multiple industries, such as software, healthcare, retail, media, agriculture, insurance, capital markets, manufacturing, cannabis, cybersecurity, and health technology. Stonehaven's commitment to innovation and technology enhances the efficiency of capital raising processes for its clients.

David Frank

CEO, Founder and Managing Partner

1 past transactions

Response Pharmaceuticals

Series A in 2022
Response Pharmaceuticals is a biotechnology and pharmaceutical company focused on developing innovative treatments for the metabolic side effects associated with antipsychotic medications. The firm is working on an iMTP inhibitor aimed at addressing issues such as weight gain and metabolic dysregulation, which can hinder patients' recovery from mental illness. By targeting these metabolic challenges, Response Pharmaceuticals aims to enhance the overall well-being of patients, enabling them to better manage both their mental health and associated physical health concerns.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.